Tempus AI and Predicta Biosciences announced a partnership to broaden the use of the GenoPredicta assay, an ultrasensitive whole‑genome sequencing (WGS) platform that integrates flow cytometry and can detect as few as 50 tumor cells—one in a million—while maintaining 100% concordance between peripheral blood and bone marrow samples.
The collaboration is designed to give Tempus AI’s life‑science partners a unified workflow that replaces siloed testing methods. By combining flow cytometry, cytogenetics, and WGS into a single assay, the partnership aims to enable earlier detection, smarter treatment decisions, and a deeper understanding of clonal evolution in blood cancers.
Tempus AI’s broader strategy has focused on expanding AI‑driven precision medicine through partnerships and acquisitions. The company reported an 83% year‑over‑year revenue growth to $1.27 billion, a market capitalization of approximately $8.89 billion, and a loss of $1.41 per share. The new partnership is expected to accelerate the adoption of the GenoPredicta assay and strengthen Tempus AI’s competitive position in the oncology diagnostics market.
Brian McKernan, CEO of Predicta Biosciences, said, "By joining forces with Tempus, we are delivering unprecedented sensitivity and clarity to researchers – enabling the potential for earlier detection, smarter treatment decisions, and a deeper understanding of disease biology from a single assay." Kate Sasser, PhD, Chief Scientific Officer at Tempus, added, "GenoPredicta offers a novel, unified solution for our life science partners and a comprehensive replacement for traditional, siloed testing. By consolidating flow cytometry, cytogenetics, and WGS into one ultrasensitive workflow, we can identify high‑risk biomarkers and track clonal evolution from as few as 50 tumor cells. Crucially, because the assay delivers 100% concordance between peripheral blood and bone marrow, it can provide these deep insights while sparing patients from biopsies."
The announcement was well received by investors, reflecting confidence in the expanded capabilities and the potential for increased revenue streams in the precision oncology diagnostics space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.